Takeda Pharmaceutical (TAK) Return on Capital Employed (2018 - 2026)

Takeda Pharmaceutical's Return on Capital Employed history runs 9 years deep, the most recent figure standing at 12.38% for Q1 2026.

• In Q1 2026, Return on Capital Employed fell 208.0% year-over-year to 12.38%; the TTM figure through Mar 2026 stood at 12.38% (down 208.0% YoY), while the FY2026 annual figure was 3.31%, up 59.0% from the prior year.
• Return on Capital Employed was 12.38% for Q1 2026 at Takeda Pharmaceutical, down from 15.78% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 16.02% in Q2 2025 to a low of 4.86% in Q2 2023.
• Historically, Return on Capital Employed has averaged 9.14% across 5 years, with a median of 6.72% in 2022.
• The sharpest annual moves came in 2025 and 2026: Return on Capital Employed jumped 1045 bps in 2025, then sank 208 bps in 2026.
• A 5-year view of Return on Capital Employed shows it stood at 6.02% in 2022, then advanced by 26 bps to 7.57% in 2023, then surged by 40 bps to 10.61% in 2024, then jumped by 49 bps to 15.78% in 2025, then dropped by 22 bps to 12.38% in 2026.
• The last three Return on Capital Employed figures came in at 12.38% (Q1 2026), 15.78% (Q4 2025), and 15.56% (Q3 2025), per Business Quant data.